Shandong Weigao Group Medical Polymer
Market Cap
US$5.6b
Last Updated
2020/03/17 01:53 UTC
Data Sources
Company Financials +
Executive Summary
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China.
Rewards
PE ratio (22.1x) is below the Medical Equipment industry average (32.7x)
Risk Analysis
No risks detected for SHWG.F from our risk checks.
Snowflake Analysis
Solid track record with excellent balance sheet.
Similar Companies
Share Price & News
How has Shandong Weigao Group Medical Polymer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SHWG.F has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0%
SHWG.F
11.3%
US Medical Equipment
5.3%
US Market
1 Year Return
n/a
SHWG.F
-4.5%
US Medical Equipment
-10.7%
US Market
Return vs Industry: Insufficient data to determine how SHWG.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how SHWG.F performed against the US Market.
Shareholder returns
| SHWG.F | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 11.3% | 5.3% |
| 30 Day | 0% | -8.5% | -13.6% |
| 90 Day | 0% | -15.6% | -19.8% |
| 1 Year | n/a | -3.8%-4.5% | -8.9%-10.7% |
| 3 Year | 98.6%98.6% | 47.0%43.0% | 15.5%8.0% |
| 5 Year | 40.1%40.1% | 78.8%60.2% | 35.2%20.4% |
Price Volatility Vs. Market
How volatile is Shandong Weigao Group Medical Polymer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Should Shandong Weigao Group Medical Polymer Company Limited (OTCPK:SHWG.F) Be Part Of Your Portfolio?Valuation
Is Shandong Weigao Group Medical Polymer undervalued compared to its fair value and its price relative to the market?
22.09x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SHWG.F ($1.11) is trading above our estimate of fair value ($0.62)
Significantly Below Fair Value: SHWG.F is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SHWG.F is good value based on its PE Ratio (22.1x) compared to the Medical Equipment industry average (32.7x).
PE vs Market: SHWG.F is poor value based on its PE Ratio (22.1x) compared to the US market (12.7x).
Price to Earnings Growth Ratio
PEG Ratio: SHWG.F is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: SHWG.F is good value based on its PB Ratio (2.5x) compared to the US Medical Equipment industry average (2.6x).
Next Steps
Future Growth
How is Shandong Weigao Group Medical Polymer forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
16.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SHWG.F's forecast earnings growth (16.7% per year) is above the savings rate (1.7%).
Earnings vs Market: SHWG.F's earnings (16.7% per year) are forecast to grow faster than the US market (12.4% per year).
High Growth Earnings: SHWG.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: SHWG.F's revenue (15% per year) is forecast to grow faster than the US market (7.5% per year).
High Growth Revenue: SHWG.F's revenue (15% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SHWG.F's Return on Equity is forecast to be low in 3 years time (13.5%).
Next Steps
Past Performance
How has Shandong Weigao Group Medical Polymer performed over the past 5 years?
15.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SHWG.F has high quality earnings.
Growing Profit Margin: SHWG.F's current net profit margins (18.3%) are higher than last year (16.8%).
Past Earnings Growth Analysis
Earnings Trend: SHWG.F's earnings have grown by 15.1% per year over the past 5 years.
Accelerating Growth: SHWG.F's earnings growth over the past year (40.2%) exceeds its 5-year average (15.1% per year).
Earnings vs Industry: SHWG.F earnings growth over the past year (40.2%) exceeded the Medical Equipment industry 4.5%.
Return on Equity
High ROE: SHWG.F's Return on Equity (11.3%) is considered low.
Next Steps
Financial Health
How is Shandong Weigao Group Medical Polymer's financial position?
Financial Position Analysis
Short Term Liabilities: SHWG.F's short term assets (CN¥11.1B) exceed its short term liabilities (CN¥3.9B).
Long Term Liabilities: SHWG.F's short term assets (CN¥11.1B) exceed its long term liabilities (CN¥5.0B).
Debt to Equity History and Analysis
Debt Level: SHWG.F's debt to equity ratio (34.4%) is considered satisfactory.
Reducing Debt: SHWG.F's debt to equity ratio has increased from 2.9% to 34.4% over the past 5 years.
Debt Coverage: SHWG.F's debt is well covered by operating cash flow (42.6%).
Interest Coverage: SHWG.F's interest payments on its debt are well covered by EBIT (18.9x coverage).
Balance Sheet
Inventory Level: SHWG.F has a high level of physical assets or inventory.
Debt Coverage by Assets: SHWG.F's debt is covered by short term assets (assets are 2x debt).
Next Steps
Dividend
What is Shandong Weigao Group Medical Polymer's current dividend yield, its reliability and sustainability?
1.36%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SHWG.F's dividend (1.36%) isn’t notable compared to the bottom 25% of dividend payers in the US market (2.06%).
High Dividend: SHWG.F's dividend (1.36%) is low compared to the top 25% of dividend payers in the US market (5.59%).
Stability and Growth of Payments
Stable Dividend: SHWG.F's dividend payments have been volatile in the past 10 years.
Growing Dividend: SHWG.F's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (28.2%), SHWG.F's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SHWG.F's dividends in 3 years are forecast to be well covered by earnings (26.9% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Jing Long (44yo)
1.58s
Tenure
CN¥2,325,000
Compensation
Mr. Long Jing has been Chief Executive Officer and Executive Director of Shandong Weigao Group Medical Polymer Company Limited since August 29, 2018. Mr. Jing serves as a Vice-General Manager of Shandong W ...
CEO Compensation Analysis
Compensation vs Market: Jing's total compensation ($USD332.54K) is below average for companies of similar size in the US market ($USD7.57M).
Compensation vs Earnings: Jing's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Compliance Officer | 4yrs | CN¥2.31m | 0.72% CN¥40.2m | |
| CEO & Executive Director | 1.58yrs | CN¥2.33m | no data | |
| Executive Director | 7yrs | CN¥10.89m | no data | |
| Chief Financial Officer | 3.08yrs | no data | no data | |
| Company Secretary | 13.83yrs | no data | no data | |
| Vice-General Manager of the Production and Supply Chain | no data | no data | no data |
3.1yrs
Average Tenure
47yo
Average Age
Experienced Management: SHWG.F's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Compliance Officer | 4yrs | CN¥2.31m | 0.72% CN¥40.2m | |
| CEO & Executive Director | 1.58yrs | CN¥2.33m | no data | |
| Executive Director | 7yrs | CN¥10.89m | no data | |
| Non Executive Director | 19.25yrs | no data | 0.34% CN¥19.0m | |
| Executive Director | 19.25yrs | CN¥1.27m | 0.52% CN¥29.1m | |
| Supervisor | no data | no data | no data | |
| Chairman of the Board of Supervisors | no data | no data | no data | |
| Independent Non-Executive Director | 8.42yrs | CN¥108.00k | no data | |
| Independent Non-Executive Director | 7.83yrs | CN¥108.00k | no data | |
| Independent Non Executive Director | 10.58yrs | CN¥154.00k | no data |
8.4yrs
Average Tenure
57yo
Average Age
Experienced Board: SHWG.F's board of directors are considered experienced (8.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Shandong Weigao Group Medical Polymer Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Shandong Weigao Group Medical Polymer Company Limited
- Ticker: SHWG.F
- Exchange: OTCPK
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: HK$43.641b
- Listing Market Cap: HK$5.618b
- Shares outstanding: 4.52b
- Website: https://www.weigaogroup.com
Number of Employees
Location
- Shandong Weigao Group Medical Polymer Company Limited
- Torch Hi-Tech Science Park
- 18 Xingshan Road
- Weihai
- Shandong Province
- 264210
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1066 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Feb 2004 |
| UK2 | DB (Deutsche Boerse AG) | Yes | Foreign Shares-Foreign Listed | DE | EUR | Feb 2004 |
| SHWG.F | OTCPK (Pink Sheets LLC) | Yes | Foreign Shares-Foreign Listed | US | USD | Feb 2004 |
| 1066 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Feb 2004 |
| 1066 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Feb 2004 |
| SHWG.Y | OTCPK (Pink Sheets LLC) | ADS REP SHS H | US | USD | Nov 2010 |
Biography
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China. The company operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. It offers vascular and non-vascular access infusion devices, including infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound healing dressings, wound sutures, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. The company also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, it engages in the production and sale of orthopedic products; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemo-dialysis equipment; and type I, type II, and type III medical devices. Further, the company is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; and provision of asset management and enterprise consulting services, as well as logistics and storage services. Shandong Weigao Group Medical Polymer Company Limited offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. The company also export its products. It serves hospitals, blood stations, and other medical units; and distributors. The company was founded in 2000 and is based in Weihai, the People’s Republic of China.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/17 01:53 |
| End of Day Share Price | 2019/12/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.